February 2010

Join WhatsApp Channel 

Crack GPAT — Prepare for GPAT Online
NEWS: Gujarat drug manufacturers resort to novel method to urge govt not to hike excise duty

Concerned over the speculation that the central government in its forthcoming budget may hike the central excise from 4 per cent to at least 8 per cent, the pharmaceutical manufacturers in Gujarat have started a new method to drive home the point that any hike in excise duty for pharma sector will result in closure of thousands of units in the country.

Work as Team Member–TTG (Analytical-Method development) at Dr. Reddy's Lab

                  Dr.

Job as Analyst-Quality Assurance & Production at Cipla

                          Cipla

Job as Analyst-Quality Assurance & Production

Job as Analyst-Quality Control at Cipla

                            Cipla

Job as Analyst-Quality Control

Work as Manager-Technical Training at Lupin Limited

                   Lupin Limited

Work as Manager-Technical Training

Work as Trainee Territory Executive (MR) in Abbott India Ltd

Abbott India Ltd

Work as Trainee Territory Executive (MR)-North India

WORK AS ASSISTANT MANAGER- PRODUCTION (PHARMA) in Sunways

Sunways

WORK AS ASSISTANT MANAGER- PRODUCTION (PHARMA)

Professors of Pharmacology and Pharmaceutics and in Lifesciences.

SGRRITS

 

Vacancy as Professors of Pharmacology and Pharmaceutics

Olanzapine Label for Adolescent Indication Changed

Changes have been made to the prescribing information for olanzapine (Zyprexa, Eli Lilly) related to its indication for use in adolescents (ages 13 - 17 years) for the treatment of schizophrenia and bipolar I disorder, the US Food and Drug Administration (FDA) announced on Friday.

The wording, described in an alert sent last week from MedWatch, the FDA's safety information and adverse event reporting program, encourages clinicians to consider potential long-term risks when prescribing to adolescents.

FDA Approves New Lidocaine-Containing Dermal Filler Formulation

The US Food and Drug Administration (FDA) has approved a new formulation for a hyaluronic acid dermal filler (Juvederm XC, Allergan, Inc) that contains a local anesthetic to enhance patient comfort when treating moderate to severe facial wrinkles and folds.

As with the original version (Juvederm, Allergan, Inc), the injectable gel product lasts up to 1 year from initial treatment. The addition of 0.3% lidocaine numbs the treatment area within seconds, potentially decreasing the need for additional anesthetic.